Valuation: Invion Limited

Market Cap 4.26M 3M 2.63M 2.47M 2.26M 4.23M 287M 29.72M 11.52M 146M 11.26M 11.02M 475M P/E 2025
-0.9x
P/E 2026 -0.56x
Enterprise Value 5.21M 3.67M 3.22M 3.03M 2.77M 5.18M 352M 36.39M 14.11M 179M 13.79M 13.49M 581M EV / Sales 2025
-
EV / Sales 2026 12.4x
Free-Float
53.34%
Yield 2025 *
-
Yield 2026 -
1 day-2.56%
1 week-2.56%
Current month+2.70%
1 month-2.56%
3 months-7.32%
6 months-50.00%
Current year-59.14%
1 week 0.04
Extreme 0.038
0.04
1 month 0.04
Extreme 0.036
0.04
Current year 0.03
Extreme 0.032
0.1
1 year 0.03
Extreme 0.032
0.11
3 years 0.03
Extreme 0.032
0.8
5 years 0.03
Extreme 0.032
3.4
10 years 0.03
Extreme 0.032
5.8
Manager TitleAgeSince
Chief Executive Officer - 2020-10-31
Director of Finance/CFO 53 2020-07-12
Investor Relations Contact 54 -
Director TitleAgeSince
Chairman - 2017-11-30
Director/Board Member 76 2019-02-11
Director/Board Member 53 2024-08-30
Change 5-day change 1-year change 3-year change Capi.($)
-2.56%-2.56%-65.45%-90.50% 3M
-0.18%+4.35%+4.23%+31.79% 47.56B
-0.83%-0.36%+43.66%+34.77% 44.09B
-0.84%+4.86%+10.92%+91.52% 41.5B
-1.10%-2.64%+331.49%+535.80% 40.88B
-0.62%+0.11%+1.12%+46.02% 29.67B
-2.07%+0.12%+24.39%+154.30% 17.23B
-3.55%+1.95%+21.97%+38.83% 15.06B
-6.08%-9.92% - - 14.65B
-0.78%+9.46%-8.96% - 13.82B
Average -1.76%-0.71%+40.37%+105.32% 26.45B
Weighted average by Cap. -1.09%+0.96%+67.22%+141.34%

Financials

2025 2026
Net sales - 385K 271K 238K 224K 204K 382K 25.95M 2.68M 1.04M 13.23M 1.02M 995K 42.9M
Net income -8.81M -6.2M -5.44M -5.12M -4.68M -8.74M -594M -61.47M -23.83M -303M -23.29M -22.78M -982M -5.63M -3.97M -3.48M -3.27M -2.99M -5.59M -380M -39.31M -15.24M -194M -14.9M -14.57M -628M
Net Debt -850K -599K -526K -494K -452K -844K -57.37M -5.93M -2.3M -29.25M -2.25M -2.2M -94.83M 955K 673K 590K 555K 507K 948K 64.44M 6.67M 2.58M 32.85M 2.53M 2.47M 107M
Logo Invion Limited
Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.
Employees
4
Date Price Change Volume
26-09-24 A$0.0380 -2.56% 123,646
26-09-18 A$0.0390 -13.33% 34,351